NEW YORK (GenomeWeb News) – Compugen said today that it will screen peptide candidates for three Pfizer drug targets.
Under the collaboration, Compugen will use its predictive models, algorithms, and computational biology methods to discover and synthesize molecules for the drug maker. Pfizer will pay Compugen for the research, and it will have the right to options for worldwide and exclusive milestones and licenses to develop and commercialize the selected candidates, Compugen said.
Compugen said it expects the studies to take a few months.
Specific financial terms of the agreement were not released.